Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a biochemical correction of the disease with minimal adverse reactions.
This article was originally published on MedicalXpress.com
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
© 2025 SimplyWell.ca